BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?
Dendritic cell (DC) vaccines show promising effects in cancer immunotherapy. However, their efficacy is affected by a number of factors, including (1) the quality of the DC vaccine and (2) tumor immune evasion. The recently characterized BDCA1+CD14+ immunosuppressive cells combine both aspects; thei...
Main Authors: | Thomas J. van Ee, Heleen H. Van Acker, Tom G. van Oorschot, Viggo F. Van Tendeloo, Evelien L. Smits, Ghaith Bakdash, Gerty Schreibelt, I. Jolanda M. de Vries |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-09-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | http://www.mdpi.com/2076-393X/6/3/65 |
Similar Items
-
Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer
by: Sévérine de Bruijn, et al.
Published: (2019-09-01) -
Intratumoral Combinatorial Administration of CD1c (BDCA-1)<sup>+</sup> Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial
by: Julia Katharina Schwarze, et al.
Published: (2020-11-01) -
Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG
by: Christina Wefers, et al.
Published: (2018-06-01) -
Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
by: Wouter W. van Willigen, et al.
Published: (2018-10-01) -
Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells
by: Jinthe Van Loenhout, et al.
Published: (2019-10-01)